glp

Documents about glp

• GLP-1 Medicines and Mental Health Changes#835830ClinicalTrials.gov
• Navigating the Gray Area: The Unregulated Surge of Unique GLP-1 and GLP-1/GIP Products#291099Digital Commons @ UConn
• The GLOW Study: GLP-1 and Lifestyle for Optimal Wellness#870480ClinicalTrials.gov
• Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists. Reply#99812PhilArchive
• Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists#722519PhilArchive
• GLP-1 Receptor Expression in CHI#852424ClinicalTrials.gov
• Expression and function of the GLP-1 receptor in the human cardiovascular system : a translational approach#330126HAL (France)
• Acupressure Wristbands for GLP-1RA Related Nausea#813703ClinicalTrials.gov
• Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation#343797ClinicalTrials.gov
• Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.#837527ClinicalTrials.gov
• Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists#805604ClinicalTrials.gov
• GLP_1 RA Ultrasound Study#992051ClinicalTrials.gov
• Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy#829644ClinicalTrials.gov
• GLP-1 and Hypoglycemia#906815ClinicalTrials.gov
• Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1#979888ClinicalTrials.gov
• Liraglutide Effects on Memory in Healthy Subjects#848683ClinicalTrials.gov
• A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570#811193ClinicalTrials.gov
• Gastric Emptying in Healthy Volunteers and GLP-1 Agonist Users#859318ClinicalTrials.gov
• The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight#838447ClinicalTrials.gov
• The Public Health Impact of GLP-1 Advertising Exposure in the U.S.#203506OSF
• GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation.#479206NCBI PubMed Central
• GLP-1 en trastornos por uso de sustancias: Neurobiología, evidencia clínica y agenda de investigación#342015DIALNET OAI Articles
• Brainstem GLP-1 neurons modulate physiological satiation and drive sustained weight loss in obese mice#182056Europe PMC
• Regulation of Insulin Secretion by the GLP-1 Receptor#864392ClinicalTrials.gov
• Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients#894580ClinicalTrials.gov
• A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use#895513ClinicalTrials.gov
• A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists#980441ClinicalTrials.gov
• GIP and GLP-1 in Type 1 Diabetes#356630ClinicalTrials.gov
• Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment#146404ClinicalTrials.gov
• GLP-1R Actions on Muscle and the Skeleton#882528ClinicalTrials.gov
• Weight and Metabolic Management Study#968344ClinicalTrials.gov
• Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity#366569ClinicalTrials.gov
• Assessing Awareness, Confidence and Utilization of Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists Among Healthcare Clinicians and Pharmacists: A Comprehensive Survey Study.#636393NCBI PubMed Central
• Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy#891806ClinicalTrials.gov
• Strength Training Response of Muscle in GLP-1 Users#916579ClinicalTrials.gov
• MadeWell: GLP-1 Beef Wellington Frozen Meal#169509ScholarsArchive@JWU
• Effects of GLP-1 on Chronic Heart Failure#414435ClinicalTrials.gov
• Glucagon-like Peptide (GLP) Utilization and Safety#668941ClinicalTrials.gov
• Reward Mechanisms in Obesity#863209ClinicalTrials.gov
• Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.#193620NCBI PubMed Central
• Impact GLP-1 Agonists Following Bariatric#828178ClinicalTrials.gov
• GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women#995095ClinicalTrials.gov
• Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics#146401ClinicalTrials.gov
• GLP-1 Infusion and Long-Time Fasting#411346ClinicalTrials.gov
• GLP-1 Receptor Agonists in the Rehabilitation of Patients with Heart Failure: Mechanisms, Clinical Evidence, and Future Perspectives#385413OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.#867367ClinicalTrials.gov
• Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss#874985ClinicalTrials.gov
• Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle#877822ClinicalTrials.gov
• Slowly Digestible Carbohydrates for GLP-1 Secretion#915558ClinicalTrials.gov
• A Study of LY3502970 in Participants With Impaired and Normal Liver Function#982097ClinicalTrials.gov